Osr Holdings Inc (OSRH) Stock Price, Quote & News

Company Profile

OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Switzerland, and South Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma that is in phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is...

Industry: Biotechnology

Sector: Healthcare

Phone: 425 635 7700

Website: www.osr-holdings.com

Address:

10900 NE 4th Street, Suite 2300, Bellevue, United States

Bearbull_Baggins Jun. 4 at 10:16 PM

$OSRH Relevant reminder

0 · Reply

Bearbull_Baggins Jun. 4 at 10:08 PM

$OSRH FWIW

0 · Reply

KeepItRealistic Jun. 4 at 9:20 PM

$OSRH you sure about that 👇

0 · Reply

JoNCherry Jun. 4 at 8:16 PM

$OSRH a good close today

0 · Reply

GaryBx105 Jun. 4 at 8:03 PM

$OSRH ceo letter no longer mentions organic growth to achieve nasdaq compliance.

3 · Reply

Frog007 Jun. 4 at 7:36 PM

$OSRH how this could be allowed? Kuk Hyoun CEO of BMCE is meaning deals with „Peter” Hwang CEO of OSRH. Retailers have no chance here. Here is no institutional. Only retailers buying. 27% has Peter’s BMCE and Peter has about 20%. Now Peter keeps issuing more stocks at discounted price to White Lion and White Lion immediately dilute at lower price to retailers

1 · Reply

JoNCherry Jun. 4 at 7:20 PM

$OSRH let’s see where it closes

0 · Reply

Frog007 Jun. 4 at 7:04 PM

$OSRH is this SCAM? Kuk Hyoun "Peter" Hwang holds dual executive leadership roles across both entities, serving as both the CEO & Director of BCM Europe AG (BCME) and the Chairman & CEO of OSR Holdings (NASDAQ: OSRH).Because of his overlapping leadership, corporate transactions between Peter Hwang’s two companies are formally categorized and scrutinized as related-party transactions under SEC guidelines.

0 · Reply

Genesys01 Jun. 4 at 5:40 PM

$OSRH I guess it is White Lion - every day they are selling between 250k and 500k shares, depending on the volume. OSRH is scratching the money for the Vaxim-Payment from us. They could tell us truth instead of playing hide and seek. But I am still

4 · Reply

ACstranger Jun. 4 at 4:33 PM

$OSRH I really wonder what entity is facking up the sp. Sell, sell and sell...

0 · Reply

OSR Holdings continues ‘to work closely’ with Nasdaq to regain compliance

Jun 3, 2026, 12:05 PM EDT - 1 day ago

CEO Statement to Shareholders

2026-05-27T15:40:49.000Z - 8 days ago

OSR Holdings acquires full VXM01 intellectual property portfolio for $30M

May 27, 2026, 9:06 AM EDT - 8 days ago

OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction

2026-05-12T19:35:00.000Z - 23 days ago

OSR Holdings CEO says company not pursuing reverse stock split

May 5, 2026, 1:05 PM EDT - 4 weeks ago

Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target

Apr 30, 2026, 9:15 AM EDT - 5 weeks ago

OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026

2026-04-29T16:28:46.000Z - 5 weeks ago

OSR Holdings enters $815M global license agreement for VXM01 with BCM Europe

Apr 29, 2026, 9:50 AM EDT - 5 weeks ago

OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe

2026-04-09T13:34:34.000Z - 2 months ago

OSR Holdings eliminates $2.02M warrant overhang

Apr 9, 2026, 9:15 AM EDT - 2 months ago

OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note

Mar 30, 2026, 9:00 AM EDT - 2 months ago

OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026

Mar 27, 2026, 9:00 AM EDT - 2 months ago

Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target

2026-03-23T12:46:05.000Z - 2 months ago

OSR Holdings announces update to $815M VXM01 licensing deal structure

Mar 23, 2026, 8:30 AM EDT - 2 months ago

OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level

2026-03-19T13:07:19.000Z - 2 months ago

OSR Holdings subsidiary signs NDA with Sinopharm

2026-03-19T13:07:07.000Z - 2 months ago

OSR Holdings subsidiary signs NDA with Sinopharm

Mar 19, 2026, 8:55 AM EDT - 2 months ago

Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities

2026-03-05T14:44:08.000Z - 3 months ago

OSR Holdings granted 180-day Nasdaq extension

Mar 5, 2026, 9:30 AM EST - 3 months ago

OSR Holdings, Inc. Granted 180-Day Nasdaq Extension; Reaffirms Strategic Momentum

2026-02-02T14:55:28.000Z - 4 months ago

OSR Holdings CEO says fundamentals of business ‘remain strong’

2026-01-27T13:50:45.000Z - 4 months ago

OSR Holdings completes Woori IO acquisition

Jan 27, 2026, 8:30 AM EST - 4 months ago

OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries

Jan 22, 2026, 9:55 AM EST - 4 months ago

Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch

Jan 16, 2026, 9:20 AM EST - 4 months ago

Vaximm Appoints Sébastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform

Jan 12, 2026, 8:05 AM EST - 5 months ago

Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones

2025-12-19T16:55:10.000Z - 5 months ago

OSR Holdings announces Woori IO shareholders approve share exchange

Dec 19, 2025, 11:50 AM EST - 5 months ago

Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings

Dec 4, 2025, 3:19 PM EST - 6 months ago

Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target Following Major Licensing Agreement

2025-12-02T15:06:23.000Z - 6 months ago

Vaximm updates term sheet with BCM Europe to shorten exclusivity period

Dec 2, 2025, 9:53 AM EST - 6 months ago

Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months

Dec 1, 2025, 3:01 PM EST - 6 months ago

OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025

2025-11-21T14:25:17.000Z - 6 months ago

OSR Holdings’ Vaximm AG enters non-binding term sheet with BCM Europe

Nov 21, 2025, 9:20 AM EST - 6 months ago

Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones

Nov 14, 2025, 11:10 AM EST - 7 months ago

OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion

2025-11-06T13:48:10.000Z - 7 months ago

OSR Holdings’ glucose monitor demonstrates accuracy and precision in pilot study

Nov 6, 2025, 8:30 AM EST - 7 months ago

OSR Holdings Announces Woori IO's Noninvasive Glucose Monitor Demonstrates High Accuracy and Precision in Company-Sponsored Pilot Study

Oct 20, 2025, 11:39 AM EDT - 8 months ago

Emerging Growth Research Initiates Coverage on OSR Holdings, Inc. with a Buy-Emerging Rating and $10.00 Price Target

2025-10-14T12:41:26.000Z - 8 months ago

OSR Holdings to acquire Woori IO for needle-free glucose monitoring

Oct 14, 2025, 8:30 AM EDT - 8 months ago

OSR Holdings Signs Definitive Agreement to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring with Potential to Transform Diabetes Care

2025-09-09T21:35:11.000Z - 9 months ago

OSR Holdings receives non-compliance letter from Nasdaq

Sep 9, 2025, 5:30 PM EDT - 9 months ago

OSR Holdings Receives Nasdaq Minimum Bid Price Deficiency Notice; Company Highlights Unusual Trading Activity

Aug 1, 2025, 1:29 PM EDT - 10 months ago

OSR Holdings to Host Virtual Investor Event Providing Key Corporate Updates and Strategic Direction on August 6, 2025

Jul 31, 2025, 12:45 PM EDT - 11 months ago

OSR Holdings Provides Transparency Update on Equity Financing Instruments

Jul 30, 2025, 4:10 PM EDT - 11 months ago

OSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange Structure

2025-07-24T11:41:06.000Z - 11 months ago

OSR Holdings to acquire glucose monitoring provider Woori IO

Jul 24, 2025, 7:30 AM EDT - 11 months ago

OSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring Technology

Jul 15, 2025, 7:30 AM EDT - 11 months ago

OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company

2025-07-09T12:05:08.000Z - 11 months ago

OSR Holdings announces strategic roadmap for tokenization

Jul 9, 2025, 7:58 AM EDT - 11 months ago

OSR Holdings Announces Strategic Roadmap for Tokenization Under Reg D Framework in Partnership with BCM Europe AG

2025-07-08T14:16:29.000Z - 11 months ago

OSR Holdings announces strategic roadmap for tokenization

May 22, 2025, 7:36 AM EDT - 1 year ago

OSR Holdings, BCM Europe, and Taekwondo Cooperative Announce Strategic MOU to Launch Blockchain-Based OSRH Token

May 2, 2025, 7:30 AM EDT - 1 year ago

Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics

Apr 9, 2025, 7:54 AM EDT - 1 year ago

Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology

Apr 3, 2025, 7:30 AM EDT - 1 year ago

OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies

Mar 26, 2025, 7:16 AM EDT - 1 year ago

Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma

Mar 25, 2025, 7:00 AM EDT - 1 year ago

OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer

Feb 14, 2025, 6:10 PM EST - 1 year ago

OSR Holdings, Inc. and OSR Holdings Co., Ltd. Announce Completion of Business Combination

Bearbull_Baggins Jun. 4 at 10:16 PM

$OSRH Relevant reminder

0 · Reply

Bearbull_Baggins Jun. 4 at 10:08 PM

$OSRH FWIW

0 · Reply

KeepItRealistic Jun. 4 at 9:20 PM

$OSRH you sure about that 👇

0 · Reply

JoNCherry Jun. 4 at 8:16 PM

$OSRH a good close today

0 · Reply

GaryBx105 Jun. 4 at 8:03 PM

$OSRH ceo letter no longer mentions organic growth to achieve nasdaq compliance.

3 · Reply

Frog007 Jun. 4 at 7:36 PM

1 · Reply

JoNCherry Jun. 4 at 7:20 PM

$OSRH let’s see where it closes

0 · Reply

Frog007 Jun. 4 at 7:04 PM

0 · Reply

Genesys01 Jun. 4 at 5:40 PM

4 · Reply

ACstranger Jun. 4 at 4:33 PM

$OSRH I really wonder what entity is facking up the sp. Sell, sell and sell...

0 · Reply

ACstranger Jun. 4 at 3:47 PM

$OSRH up to $5. come on!

0 · Reply

FleeceWood_Mac Jun. 4 at 3:41 PM

$OSRH let’s see .46 today and up ⬆️

0 · Reply

IldijanaMM Jun. 4 at 2:41 PM

$OSRH The 5 proposals for the meeting 18/6 😉 no R/S on the table!

1 · Reply

JoNCherry Jun. 4 at 1:48 PM

$OSRH seems people aren’t buying 800M deal, either they need some upfront payment or a clinical start or maybe something different…

0 · Reply

IldijanaMM Jun. 4 at 8:15 AM

$OSRH 🤩 wow this is the guy promising no R/S Kuk Hyoun Hwang is the Chief Executive Officer of the Zug, Switzerland-based private investment firm BCM Europe AG.The healthcare and blockchain investment firm frequently operates through investment vehicles and funds and is notably the majority shareholder of OSR Holdings. BCM Europe made headlines in early 2026 by entering into an $815 million definitive global exclusive license agreement for the development and commercialization of the VXM01 oral immunotherapy with OSR Holdings. BCMGlobal (European Credit/Mortgage Services): The CEO of BCMGlobal is Antoinette Dunne. The company handles massive asset portfolios across Europe and is part of LC Financial Holdings, which manages over €100 billion in assets LOAD THE FOOKING BOAT

2 · Reply

IldijanaMM Jun. 4 at 8:05 AM

$OSRH 10$ 🎯 It would make a cap of 350M$ Peanuts based on deal signed of 815M$

1 · Reply

Rebirth_Coldblooded Jun. 4 at 3:53 AM

$OSRH this needs to enter clinical trial registration. I just learned that they have been working on this deal since November 2025, so all these ducks should be in a row or close. Speculating they hit a setback which prompted the ceo spit today and mentioning Woori. Time for full throttle Hwang. Also, OSRH = public company BCM Europe = largest shareholder of OSRH BCM Europe = counterparty in the VXM01 licensing deal Kuk Hyoun Hwang = CEO of OSRH Kuk Hyoun Hwang = CEO of BCM Europe Kuk Hyoun Hwang = Chairman of Vaximm AG, which owns VXM01. Seems streamlined for funding if you ask me.

0 · Reply

GoldManStackz Jun. 4 at 3:44 AM

$BURU another @JJBurch special for yall, he’ll bankrupt you. Look at how he pounded the table on $IXHL and $QCLS and $OSRH. Never been right, never will be

1 · Reply

Frog007 Jun. 4 at 1:59 AM

$BTC.X bearly 7% and you cry? Come to $OSRH, we had this every single day for last 2 weeks but starting tomorrow we fly.

1 · Reply

Genesys01 Jun. 4 at 1:30 AM

$OSRH For sure a good Woori deal for a big market or integration into a smart watch. This would not bring it to 5$ minimum.

0 · Reply

stefangl Jun. 4 at 1:04 AM

$OSRH we need something good for this to spike. What you thing is a good PR that can spike this to $1? Real answer, real probability only

2 · Reply

KeepItRealistic Jun. 3 at 11:04 PM

$OSRH more green tomorrow 👇 Congratulations to all the smart investors who bought the bottom today

1 · Reply

Market Cap	15.29M
Revenue (ttm)	2.91M
Net Income (ttm)	-27.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-929.90%
Debt to Equity Ratio	0.04

Volume	903,100
Avg Vol	7,912,394
Day's Range	N/A - N/A
Shares Out	35.11M
Stochastic %K	0%
Beta	0.86
Analysts	Strong Buy
Price Target	N/A